8 / 19
Page 30
Notes:
conferenceseries
.com
Volume 7, Issue 4(Suppl)
J Gastrointest Dig Syst, an open access journal
ISSN: 2161-069X
Gastro Congress 2017
September 11-12, 2017
September 11-12, 2017 | Paris, France
12
th
Euro-Global Gastroenterology Conference
Toward understanding the molecular basis of esophageal squamous cell carcinoma
Ming Rong Wang
Cancer Institute and Hospital - CAMS & PUMC, China
E
sophageal squamous cell carcinoma (ESCC) is among the most common human cancers, with an overall five-year survival rate of
around 20%. To improve the diagnosis and prognosis of ESCC, we performed systematic studies on the molecular alterations in
the disease. Frequent gains of chromosomal bands 3q26, 8q24, 11q13, losses of 3p14 and 9p21, amplifications of genes CCND1, EMS1
(CTTN), EGFR, PLK1, SKP2, PRKCI (PKCiota), deletions of CDKN2A/B, FHIT, and rearrangements of NTRK3, DTL, and PTPRD
were found. The mutation profiling was characterized, and potential therapeutic targets were identified. We further investigated
intratumor heterogeneity (ITH) of the molecular alterations, and constructed phylogenetic trees for genomic evolution, in which the
mutations of ERBB4, FGFR2, BRCA2, ATM, TP53 and copy number changes of 11q13 and 9p21 were early events, and those of PI3K/
MTOR pathway, KIT, AURKA, CCND2 and 3q26 were late. By proteomic techniques and immunohistochemistry, multiple proteins
were observed with high expression in tumor tissues but negative/low expression in morphologically normal operative margins.
Especially, copy number alterations of ANO1, CDKN2A, and high expression of p63 and ANO1 were also present in precancerous
lesions (dysplasia). We further explored the mechanisms underlying the development and progression of ESCC, and revealed that
CRT, CTTN, PKCiota, SKP2 and PLK1 enhanced cell motility and resistance to apoptosis, and promoted tumor growth and metastasis
via activating the PI3K-AKT pathway, inhibiting beta-catenin degradation, and up-regulating the apoptosis suppressor Survivin.
These findings extend our understanding of ESCC, providing theoretical foundation for elucidating the mechanisms underlying the
tumorigenesis of the esophagus and progression of ESCC, and for developing classification biomarkers and therapy targets for ESCC
treatment.
Biography
Ming Rong Wang is a Professor and Principle Investigator in State Key Laboratory of Molecular Oncology, Peking Union Medical College and Chinese Academy
of Medical Sciences. He received his PhD at University of Clermont I, France in 1993. He has spent most of his scientific carrier in the study of human cancer. His
research interests cover cancer genetics and molecular cell biology, including molecular basis of precancerous lesions, molecular classification of cancer, and the
mechanisms of cancer metastasis. Recently, he has focused on biomarkers for early detection of cancer, especially for esophageal squamous cell carcinoma, one
of the most common malignancies.
wangmr2015@126.comMing Rong Wang, J Gastrointest Dig Syst 2017, 7:4(Suppl)
DOI: 10.4172/2161-069X-C1-052